Financial Performance - Net revenues for Q3 2025 were $118.9 million, a 2.4% increase from $115.8 million in Q3 2024[11] - Gross profit for Q3 2025 was $64.9 million, compared to $63.2 million in Q3 2024, reflecting a gross margin improvement[11] - Operating expenses increased to $68.8 million in Q3 2025 from $51.6 million in Q3 2024, primarily due to higher research and development costs[11] - The company reported a net loss of $1.4 million in Q3 2025, a significant decline from a net income of $14.3 million in Q3 2024[11] - Basic earnings per share for Q3 2025 were $(0.02), down from $0.25 in Q3 2024[11] - Total comprehensive loss for Q3 2025 was $(1.3) million, compared to a comprehensive income of $18.5 million in Q3 2024[14] - Net income for the nine months ended September 30, 2025, was $8,803,000, a decrease of 61.9% compared to $23,094,000 for the same period in 2024[19] - The Company’s operating loss for the three months ended September 30, 2025, was $(3.95) million, compared to an operating income of $11.6 million in the same period of 2024[90] Cash Flow and Equity - Net cash provided by operating activities increased to $85,312,000 for the nine months ended September 30, 2025, compared to $66,455,000 in 2024, reflecting a growth of 28.3%[19] - Cash and cash equivalents at the end of the period were $48,646,000, down from $58,469,000 at the end of the previous period, a decrease of 16.5%[19] - Total stockholders' equity decreased to $672.0 million as of September 30, 2025, from $749.2 million a year earlier[17] - Net cash used in financing activities was $128,325,000 for the nine months ended September 30, 2025, compared to $54,379,000 in 2024, indicating a significant increase in cash outflows[19] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $76.8 million, up from $75.1 million in the same period of 2024[11] - Research and development expenses for the three months ended September 30, 2025, were $23.8 million, compared to $22.8 million in the same period of 2024, reflecting an increase of approximately 4.4%[90] Stock and Shareholder Actions - The company repurchased $64.0 million of common stock during the nine months ended September 30, 2025[17] - The Company repurchased 919,000 shares of common stock during the three months ended September 30, 2025, and 2,028,000 shares during the nine months ended September 30, 2025[67][68] - As of September 30, 2025, the outstanding common stock shares were 55,312,000, down from 56,840,000 at the same time in 2024[67] - The Company declared cash dividends of $0.21 per share for the three months ended September 30, 2025, compared to $0.20 per share in the same period of 2024, reflecting a 5% increase[74] - Total cash dividends declared and paid for the nine months ended September 30, 2025, amounted to $35.6 million, up from $34.1 million in the same period of 2024[74] Customer and Sales Information - The top ten customers accounted for approximately 81% of net revenues for both the three and nine months ended September 30, 2025, compared to 78% for the same periods in 2024[59] - Sales to distributors were $82.3 million and $238.7 million for the three and nine months ended September 30, 2025, respectively, compared to $80.5 million and $220.4 million in the same periods of 2024[59] - Geographic net revenues for the Americas were $6.2 million for the three months ended September 30, 2025, and $17.7 million for the nine months ended September 30, 2025, showing growth from $5.5 million and $15.8 million in 2024[66] Legal and Acquisition Activities - The Company recognized a charge of $9.2 million in other operating expenses related to a jury verdict in favor of the plaintiff for claims of harassment based on disability and retaliation[95] - An additional $0.7 million was recognized in the quarter ended September 30, 2025, related to plaintiff attorney fees and costs[95] - The total potential exposure related to the litigation amounts to an additional $5.2 million in expenses[95] - The Company acquired Odyssey Semiconductor Technologies for $9.52 million in cash to enhance its development of high-power GaN switching technology[100] - Goodwill from the acquisition is expected to be deductible over 15 years for tax purposes[101] - The fair value of in-process research and development will be recorded as an intangible asset with an indefinite life until completion[102] Management and Governance - The Company’s Chief Financial Officer resigned effective October 4, 2025, with an interim CFO appointed[104] - The Company maintained a valuation allowance on its deferred tax assets in California and New Jersey as of September 30, 2025, indicating ongoing tax strategy considerations[82] Marketable Securities and Investments - The total fair value of the company's cash equivalents and short-term marketable securities as of September 30, 2025, was $196,485,000, down from $252,388,000 at December 31, 2024, representing a decrease of 22.2%[37] - The company reported a total marketable securities value of $193,214,000 as of September 30, 2025, compared to $249,023,000 at December 31, 2024, reflecting a decline of 22.5%[40] - The company classified its marketable securities as available-for-sale, with a total amortized cost of $191,170,000 and gross unrealized gains of $2,045,000 as of September 30, 2025[40] - The fair value measurement of corporate securities at September 30, 2025, included $191,733,000 classified under Level 2 of the fair-value hierarchy[37] - The company holds corporate securities with an amortized cost of $155,800,000 due in 12 months or greater, with an estimated fair market value of $157,636,000[40] - The company expects the fair value of its marketable securities to recover as they reach maturity, despite current declines due to interest rate changes[45]

NORTH BETHESDA, Md., November 5, 2025 – Choice Hotels International, Inc. ("Choice" or "the Company") (NYSE: CHH), a leading global lodging franchisor, today reported results for the third quarter ended September 30, 2025. Highlights include: • Net income grew to $180.0 million for third quarter 2025 from $105.7 million in the same period of 2024, representing diluted EPS of $3.86, an increase from $2.22 in third quarter 2024. • Adjusted EBITDA for third quarter 2025 increased 7% to a third-quarter record o ...

Financial Performance - Net sales for the first quarter of fiscal 2026 increased by 9.7%, or $7.1 million, to $80.0 million compared to $72.9 million in the same quarter last year [111]. - Gross profit margin improved to 28.7% in the first quarter of fiscal 2026, up from 26.5% in the same period last year, reflecting successful margin improvement initiatives [114]. - The acquisition of Kobelt contributed $3.1 million in additional revenue during the quarter, with significant growth in demand for Veth propulsion systems [111]. - The North American region saw a revenue increase of $8.7 million (48.9%) due to the Kobelt acquisition and expansion of Veth product sales [111]. - The distribution segment experienced a sales decrease of $7.8 million (26.4%) compared to the prior year, primarily due to reduced demand for commercial marine products in Asia [113]. Expenses and Costs - Marketing, engineering and administrative expenses increased by $1.2 million (6.2%) to $20.7 million, representing 25.9% of net sales, down from 26.7% in the prior year [115]. - Total borrowings and long-term debt increased by $12.3 million to $43.7 million, with negative free cash flow reported at $11.0 million due to unfavorable working capital movements [125]. - The effective tax rate for the first quarter of fiscal 2026 was 172.2%, a significant change from (29.2%) in the prior year, influenced by a full domestic valuation allowance [117]. Assets and Liabilities - Trade receivables increased by $5.0 million (8.5%) to $63.9 million, with a notable increase in the percentage of sales to 79.9% compared to 70.7% in the prior year [120]. - Inventories rose by $6.3 million (4.2%) to $158.3 million, with a backlog of orders approximating $163.3 million, up from $150.5 million at the end of June 2025 [121]. Debt and Compliance - The Company's Total Funded Debt to EBITDA ratio must not exceed 3.50 to 1.00, and the Fixed Charge Coverage Ratio must not be less than 1.10 to 1.00 [133]. - The Company has pledged 65% of its equity interests in certain foreign subsidiaries as part of the Credit Agreement [134]. - Management believes that available cash, the Credit Agreement, and cash generated from future operations will be adequate to fund the Company's cash and capital requirements for the foreseeable future [136]. - The Company remains in compliance with its liquidity and other covenants [136]. Future Obligations and Risks - The Company expects to contribute $0.5 million to postretirement benefits and $0.7 million to its defined benefit pension plans in fiscal 2026 [137]. - The Company has long-term obligations related to its postretirement plans, which can vary significantly from year to year due to self-insurance [137]. - The Company has no material undisclosed guarantees and no additional material purchase obligations other than those related to inventory and property, plant, and equipment [137]. Agreements and Disclosures - The Company has amended various agreements to secure borrowings under the Credit Agreement, including a Security Agreement and IP Security Agreement [134]. - The Company is electing not to provide market risk disclosures due to its status as a Smaller Reporting Company [142]. - There have been no significant changes to the Company's critical accounting policies since June 30, 2025 [141].

Financial Performance - Investors Title Company reported a net income of $12.2 million, or $6.45 per diluted share, for Q3 2025, compared to $9.3 million, or $4.92 per diluted share, in Q3 2024, representing a 31.2% increase in net income year-over-year [1]. - Income before income taxes for Q3 2025 was $15.1 million, up from $11.6 million in Q3 2024, marking a 29.9% increase [4]. - For the nine months ended September 30, 2025, net income increased to $27.7 million, or $14.59 per diluted share, compared to $22.7 million, or $12.02 per diluted share, in the prior year period [5]. - The company noted that adjusted income before income taxes (non-GAAP) for Q3 2025 was $13.0 million, compared to $10.6 million in Q3 2024, representing a 22.6% increase [4]. Revenue Growth - Revenues increased by 6.1% to $73.0 million in Q3 2025, up from $68.8 million in Q3 2024, driven by growth in title insurance revenues and non-title services [2]. - Non-title services revenue rose by $2.0 million, primarily due to increases in revenue from like-kind exchanges and management services [2]. - Total revenues for the nine months ended September 30, 2025, rose by 8.3% to $203.2 million, up from $187.7 million in the prior year [5]. Operating Expenses - Operating expenses increased by 1.2% to $57.9 million in Q3 2025, compared to $57.2 million in Q3 2024, largely due to higher agent commissions [3]. Market Conditions - The increase in title insurance volumes reflects efforts to grow market share and favorable market conditions, including a decline in mortgage rates [6]. - The company experienced a strong open order pipeline heading into Q4 2025, indicating potential continued growth [7].

Exhibit 99.1 Twin Disc Announces First Quarter Results MILWAUKEE, Wis., November 5, 2025 (GLOBE NEWSWIRE) -- Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the first quarter ended September 26, 2025. Fiscal First Quarter 2026 Highlights CEO Perspective "We delivered a solid start to the year, with sales and margin growth that reflects the benefits of our operational discipline and the strength of our diversified end markets. In the Defense market, orders continued to accelerate, lifting six-month ...

Financial Performance - Total revenue for Q3 2025 was $1.765 million, a significant increase from $560,000 in Q3 2024, representing a growth of 215% year-over-year[14] - Product revenue for the nine months ended September 30, 2025, reached $4.252 million, compared to $1.123 million for the same period in 2024, marking an increase of 278%[14] - For the nine months ended September 30, 2025, total revenue was $32.5 million, significantly up from $1.1 million in the same period of 2024, indicating a 2,841% increase[141] - The company reported net product revenue of $1.6 million for the three months ended September 30, 2025, an increase from $0.6 million in the same period of 2024, and total net revenue of $4.3 million for the nine months ended September 30, 2025, compared to $1.1 million for the same period in 2024[82] - For the three months ended September 30, 2025, the company recognized $1.8 million in revenue from external customers, compared to $0.6 million for the same period in 2024, representing a 196% increase[140] Net Loss and Expenses - The company reported a net loss of $29.815 million for Q3 2025, compared to a net loss of $36.696 million in Q3 2024, indicating an improvement of 18%[14] - For the nine months ended September 30, 2025, the company reported a net loss of $55.3 million, compared to a net income of $2.4 million for the same period in 2024[25] - The net loss for the three months ended September 30, 2025, was $29.8 million, compared to a net loss of $36.7 million for the same period in 2024, indicating an improvement of 18.9%[14] - Direct research and development expenses for the three months ended September 30, 2025, were $10.3 million, compared to $9.7 million in the same period of 2024, showing an increase of 6.4%[141] - Research and development expenses for Q3 2025 were $17.337 million, a decrease of 10% from $19.173 million in Q3 2024[14] Cash and Liquidity - Cash and cash equivalents increased to $69.632 million as of September 30, 2025, up from $55.699 million at the end of 2024, reflecting a growth of 25%[11] - As of September 30, 2025, total cash, cash equivalents, and restricted cash amounted to $70,435 thousand, an increase from $56,475 thousand as of December 31, 2024, representing a 24.5% increase[55] - The company reported a net cash used in operating activities of $70,091,000 for the nine months ended September 30, 2025, compared to $97,906,000 for the same period in 2024[25] - The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months[40] - As of September 30, 2025, the company had $122.2 million in cash, cash equivalents, and short-term marketable securities, with an accumulated deficit of $570.6 million[37] Assets and Liabilities - Total assets as of September 30, 2025, were $163.555 million, an increase of 12% from $146.447 million at the end of 2024[11] - Total liabilities decreased to $101.936 million as of September 30, 2025, down from $124.298 million at the end of 2024, representing a reduction of 18%[11] - The company’s accumulated deficit increased to $570.629 million as of September 30, 2025, compared to $515.355 million at the end of 2024[11] - The total stockholders' equity rose to $61.6 million as of September 30, 2025, compared to $22.1 million as of December 31, 2024, representing a substantial increase of 178.3%[11] Stock and Shareholder Information - The weighted average shares outstanding for basic net loss per share increased to 43,272,773 in Q3 2025, compared to 6,695,509 in Q3 2024[14] - The company executed a 1-for-30 reverse stock split on April 28, 2025, affecting all common stock share amounts retroactively[8] - The company excluded 15,633 potential shares of common stock from the computation of diluted net loss per share for the three months ended September 30, 2025, due to their anti-dilutive effect[70] - The company’s weighted average shares of common stock outstanding for the three months ended September 30, 2025, were 43,272,773 for both basic and diluted calculations[67] Clinical Development and Regulatory Status - The company is progressing in its pivotal Phase 3 clinical trial (the "4WARD" trial) for mavorixafor, with full enrollment expected in Q3 2026[28] - The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, a rare blood condition[28] - The company has one commercially approved product, XOLREMDI® (mavorixafor), for patients with WHIM syndrome[28] Strategic Restructuring - The company implemented a strategic restructuring in Q1 2025, resulting in a 30% reduction of its workforce, incurring charges of approximately $2.3 million for severance and related costs[74] - An additional strategic restructuring was announced on September 17, 2025, leading to a further workforce reduction of approximately 50%, with expenses of about $4.9 million for severance and related costs[75] Agreements and Contracts - The Company has entered into a license and supply agreement with Norgine Pharma UK Limited, which includes multiple performance obligations and various payment structures[46] - The company entered into a License and Supply Agreement with Norgine on January 13, 2025, receiving a one-time upfront payment of €28.5 million and a regulatory milestone payment of €0.5 million, with potential future payments totaling up to €225.6 million[79][80] Marketable Securities and Investments - The Company’s available-for-sale debt marketable securities as of September 30, 2025, had a fair value of $52.6 million[59] - The company incurred an unrealized loss on marketable securities of $10,000 for the three months ended June 30, 2025[25] Other Financial Metrics - The company recorded a change in fair value of warrant liability of $(12.8) million for the nine months ended September 30, 2025[25] - The fair value of the embedded derivative liability related to the Hercules Loan Agreement was estimated at $10 thousand as of September 30, 2025[60][62] - The Class C Warrant liability decreased from $13,755 thousand as of December 31, 2024, to $959 thousand as of September 30, 2025, reflecting a significant change in fair value[60][63]

FDA Approval and Product Launch - VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval for presbyopia treatment, impacting approximately 128 million adults in the U.S.[2] - Over 2,500 Eye Care Professionals (ECPs) have prescribed VIZZ, with 40% prescribing multiple times, resulting in over 5,000 prescriptions filled through October 2025[1][9] - A partnership with Sarah Jessica Parker as a direct-to-consumer campaign spokesperson is set to launch in Q1 2026[1][9] Financial Performance - Net loss for Q3 2025 was $16.7 million, or $0.59 per share, compared to a net loss of $10.2 million, or $0.38 per share, in Q3 2024[7] - Total revenue for Q3 2025 was $12.5 million, with license revenue contributing $12.5 million, compared to no revenue in Q3 2024[22] - Total operating expenses for the nine months ended September 30, 2025, were $70.2 million, compared to $43.4 million during the same period in 2024[22] Expenses Overview - Selling, General and Administrative (SG&A) expenses increased to $27.6 million for Q3 2025, compared to $6.5 million in Q3 2024, primarily due to increased personnel-related expenses[5] - Research and Development (R&D) expenses decreased to $3.8 million for Q3 2025, down from $6.5 million in Q3 2024, driven by reduced clinical trial-related expenses[6] Cash Position and Funding - Pro forma cash, cash equivalents, and marketable securities were approximately $324.0 million as of September 30, 2025, anticipated to fund operations to post-launch positive cash flow[4] - The company achieved $10 million in milestone payments under its agreement with CORXEL Pharmaceuticals in China, including NDA submission for LNZ100[9]

Product Approval and Market Impact - VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval for presbyopia treatment, impacting approximately 128 million adults in the U.S.[2] Prescription and Usage - Over 2,500 Eye Care Professionals (ECPs) have prescribed VIZZ, with 40% prescribing multiple times, resulting in over 5,000 prescriptions filled through October 2025[1][9] Financial Position - Pro forma cash, cash equivalents, and marketable securities were approximately $324.0 million as of September 30, 2025, anticipated to fund operations to post-launch positive cash flow[4] Expenses - Selling, General and Administrative (SG&A) expenses increased to $27.6 million for Q3 2025, compared to $6.5 million in Q3 2024, primarily due to increased personnel-related expenses[5] - Research and Development (R&D) expenses decreased to $3.8 million for Q3 2025, down from $6.5 million in Q3 2024, driven by reduced clinical trial-related expenses[6] Net Loss - Net loss for Q3 2025 was $16.7 million, or $0.59 per share, compared to a net loss of $10.2 million, or $0.38 per share, in Q3 2024[7][22] Milestones and Partnerships - The company achieved $10 million in milestone payments under its agreement with CORXEL Pharmaceuticals in China, including NDA submission for LNZ100[9] - A partnership with Sarah Jessica Parker as a direct-to-consumer campaign spokesperson is set to launch in Q1 2026[1][9] Revenue - Total revenue for Q3 2025 was $12.5 million, with license revenue contributing $12.5 million, compared to no revenue in Q3 2024[22] - Total operating expenses for the nine months ended September 30, 2025, were $70.2 million, compared to $43.4 million during the same period in 2024[22]

Financial Performance - Revenues for Q3 2025 were $118.9 million, a 3% increase year-over-year and quarter-over-quarter[1] - GAAP net loss for Q3 2025 was $1.4 million, or $0.02 per diluted share, compared to net income of $0.25 per diluted share in Q3 2024[1][2] - Non-GAAP net income for Q3 2025 was $20.2 million, or $0.36 per diluted share, down from $0.40 per diluted share in Q3 2024[2] - GAAP gross profit for Q3 2025 was $64,851 million, with a gross margin of 54.5%[15] - Non-GAAP gross profit for Q3 2025 was $65,515 million, with a non-GAAP gross margin of 55.1%[15] - GAAP net loss for Q3 2025 was $1,356 million, while non-GAAP net income was $20,194 million[16] - Non-GAAP net income per share (diluted) for Q3 2025 was $0.36, compared to $0.40 in Q3 2024[16] - Net income for the three months ended September 30, 2025, was a loss of $1,356 million, compared to a profit of $1,369 million in the previous quarter[20] Cash Flow and Assets - Cash flow from operations for Q3 2025 was $29.9 million[1] - Cash provided by operating activities for the nine months ended September 30, 2025, was $85,312 million, an increase from $66,450 million in the same period of 2024[20] - Cash and cash equivalents decreased to $48,646 million from $50,972 million at the end of 2024[18] - Cash and cash equivalents at the end of the period on September 30, 2025, were $48,646 million, down from $66,935 million at the end of the previous quarter[20] - Total current assets as of September 30, 2025, were $456,063 million, down from $514,039 million at the end of 2024[18] - Total liabilities as of September 30, 2025, were $100,554 million, an increase from $79,054 million at the end of 2024[18] - Retained earnings as of September 30, 2025, were $673,218 million, down from $734,039 million at the end of 2024[18] Operational Metrics - The industrial business saw a 20% year-over-year growth in Q3 2025, while consumer appliance orders remained soft[3] - GAAP operating expenses for Q3 2025 increased to $68,804 million, compared to $51,589 million in Q3 2024[15] - Non-GAAP income from operations for Q3 2025 was $18,124 million, resulting in a non-GAAP operating margin of 15.2%[15] - Depreciation expense for the three months ended September 30, 2025, was $6,542 million, down from $7,002 million in the previous quarter[20] - Stock-based compensation expense increased to $21,205 million for the three months ended September 30, 2025, compared to $10,077 million in the previous quarter[20] Shareholder Returns - Power Integrations repurchased 919 thousand shares for $42.4 million during the quarter[4] - The company announced a quarterly dividend increase to $0.215 per share for each quarter of 2026[4] Future Projections - For Q4 2025, revenues are expected to be between $100 million and $105 million[8] - GAAP gross margin for Q4 2025 is projected to be between 53% and 53.5%[8] - GAAP operating expenses for Q4 2025 are expected to be approximately $56 million[8] Investment Activities - Net cash provided by investing activities for the three months ended September 30, 2025, was $3,543 million, compared to $32,618 million in the previous quarter[20] - Purchases of property and equipment for the three months ended September 30, 2025, totaled $5,694 million, slightly lower than $5,926 million in the previous quarter[20] - Proceeds from sales and maturities of marketable securities for the nine months ended September 30, 2025, were $116,658 million, up from $103,800 million in the same period of 2024[20] Credit and Allowance - The company reported a decrease in accounts receivable allowance for credit losses of $381 million for the nine months ended September 30, 2025, compared to a decrease of $459 million in the same period of 2024[20]

Financial Performance - ACM Research announced preliminary unaudited revenue for Q3 2025, details to be provided in the press release[4] Company Information - The company is listed on The Nasdaq Stock Market under the trading symbol ACMR[2] - The report was signed by Mark McKechnie, Chief Financial Officer and Treasurer, on October 29, 2025[11]